Skip to main content

22-05-2019 | Respiratory | Video

ATS 2019: Support for inhaled NO use in patients with ILD

Steven Nathan reports the results of an 8-week randomised placebo-controlled trial in which inhaled nitric oxide was associated with an increase in actigraphy-measured physical activity among interstitial lung disease patients at risk of pulmonary hypertension (5:12).

Funding for independent interviews at ATS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.